Celsion

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Celsion and buy or sell other stocks, ETFs, and their options commission-free!

About CLSN

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. 

CEO
Stacy R. Lindborg, PhD
CEOStacy R. Lindborg, PhD
Employees
25
Employees25
Headquarters
Lawrenceville, New Jersey
HeadquartersLawrenceville, New Jersey
Founded
1982
Founded1982
Employees
25
Employees25

CLSN Key Statistics

Market cap
20.27M
Market cap20.27M
Price-Earnings ratio
-0.31
Price-Earnings ratio-0.31
Dividend yield
Dividend yield
Average volume
29.45K
Average volume29.45K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$41.22
52 Week high$41.22
52 Week low
$2.99
52 Week low$2.99

Stock Snapshot

The current Celsion(CLSN) stock price is $7.00, with a market capitalization of 20.27M. The stock trades at a price-to-earnings (P/E) ratio of -0.31.

On 2026-02-23, Celsion(CLSN) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 29.45K.

The stock's 52-week range extends from a low of $2.99 to a high of $41.22.

The stock's 52-week range extends from a low of $2.99 to a high of $41.22.

People also own

Based on the portfolios of people who own CLSN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.